Prognostic Biomarkers for Hodgkin Lymphoma (Q38588503)

4 September 2017

title

Prognostic Biomarkers for Hodgkin Lymphoma (English)

1 reference

4 September 2017

0 references

Christine Mauz-Körholz

object named as

Christine Mauz-Körholz

1 reference

4 September 2017

Martin S Staege

1 reference

4 September 2017

Stefanie Kewitz

1 reference

4 September 2017

Toralf Bernig

1 reference

4 September 2017

Caspar Kühnöl

1 reference

4 September 2017

publication date

18 September 2015

1 reference

Pediatric Hematology and Oncology

4 September 2017

published in

1 reference

4 September 2017

1 reference

4 September 2017

1 reference

4 September 2017

page(s)

433-454

1 reference

Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin's lymphoma: the GPOH-HD-2002 study

4 September 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

Treatment of children and adolescents with Hodgkin lymphoma without radiotherapy for patients in complete remission after chemotherapy: final results of the multinational trial GPOH-HD95.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

High risk of subsequent neoplasms continues with extended follow-up of childhood Hodgkin's disease: report from the Late Effects Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

The disappearance of prognostic factors in Hodgkin's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

The World Health Organization Classification of Neoplastic Diseases of the Hematopoietic and Lymphoid Tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

Molecular biology of Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

EBV-associated lymphoproliferative disorders: classification and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

Epstein-barr virus and hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

Contribution of the Epstein Barr virus to the molecular pathogenesis of Hodgkin lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

Measles virus: evidence of an association with Hodgkin's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

Measles virus and classical Hodgkin lymphoma: no evidence for a direct association

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

Detection of Torque teno virus in Epstein-Barr virus positive and negative lymph nodes of patients with Hodgkin lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

Involvement of human herpesvirus-6 variant B in classic Hodgkin's lymphoma via DR7 oncoprotein.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

Simultaneous detection of reverse transcriptase and high molecular weight RNA in tissue of patients with Hodgkin's disease and patients with leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

Presence of human herpes virus 6 (HHV6) in pediatric lymphomas: impact on clinical course and association with cytomegalovirus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma: correlative analysis from a large North American cooperative group trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

Clonal deleterious mutations in the IkappaBalpha gene in the malignant cells in Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

Mutations of NFKBIA, encoding IkappaB alpha, are a recurrent finding in classical Hodgkin lymphoma but are not a unifying feature of non-EBV-associated cases

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

Frequent inactivation of A20 in B-cell lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

Deletion of the TNFAIP3/A20 gene detected by FICTION analysis in classical Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

A genome-wide association study of Hodgkin's lymphoma identifies new susceptibility loci at 2p16.1 (REL), 8q24.21 and 10p14 (GATA3)

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

Molecular Karyotypes of Hodgkin and Reed–Sternberg Cells at Disease Onset Reveal Distinct Copy Number Alterations in Chemosensitive versus Refractory Hodgkin Lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

An endotoxin-induced serum factor that causes necrosis of tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

Coley's toxins, tumor necrosis factor and cancer research: a historical perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

Eiger, a TNF superfamily ligand that triggers the Drosophila JNK pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

Evolution of TNF signaling mechanisms: JNK-dependent apoptosis triggered by Eiger, the Drosophila homolog of the TNF superfamily

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

Molecular cloning, characterization and expression analysis of the tumor necrosis factor (TNF) superfamily gene, TNF receptor superfamily gene and lipopolysaccharide-induced TNF-α factor (LITAF) gene from Litopenaeus vannamei

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

The TNF family in T cell differentiation and function--unanswered questions and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

The Clinical Significance of Cytokines and Soluble Forms of Membrane-Derived Activation Antigens in the Serum of Patients with Hodgkin's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

Plasma levels of tumour necrosis factor and its soluble receptors correlate with clinical features and outcome of Hodgkin's disease patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

Prognostic significance of pretreatment serum cytokines in classical Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

Recombinant human tumor necrosis factor-alpha: effects on proliferation of normal and transformed cells in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

in situ expression of the IL‐I‐α and tnf‐α genes by reed‐sternberg cells in Hodgkin's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

Lymphotoxin, tumour necrosis factor and interleukin-6 gene transcripts are present in Hodgkin and Reed-Sternberg cells of most Hodgkin's disease cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

Regression of Hodgkin lymphoma after discontinuation of a tumor necrosis factor inhibitor for Crohn's disease: a case report and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

Wengen, a member of the Drosophila tumor necrosis factor receptor superfamily, is required for Eiger signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

Hodgkin's Disease and Anaplastic Large Cell Lymphoma Revisited. 1. unique cytokine and cytokine receptor profile distinguished from that of non-hodgkin's lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

TNF-alpha-converting enzyme (TACE/ADAM17)-dependent loss of CD30 induced by proteasome inhibition through reactive oxygen species

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

Osteoprotegerin: multiple partners for multiple functions

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

Gene expression profiles of Hodgkin's lymphoma cell lines with different sensitivity to cytotoxic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

Rocaglamide and a XIAP inhibitor cooperatively sensitize TRAIL-mediated apoptosis in Hodgkin's lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

Bortezomib induces caspase-dependent apoptosis in Hodgkin lymphoma cell lines and is associated with reduced c-FLIP expression: a gene expression profiling study with implications for potential combination therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

Association of polymorphisms in TRAIL1 and TRAILR1 genes with susceptibility to lymphomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

Hodgkin lymphoma cells express TACI and BCMA receptors and generate survival and proliferation signals in response to BAFF and APRIL

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

APRIL is overexpressed in cancer: link with tumor progression

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

Multiple pathways of TWEAK-induced cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

TWEAK induces apoptosis through a death-signaling complex comprising receptor-interacting protein 1 (RIP1), Fas-associated death domain (FADD), and caspase-8

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

The tumor necrosis factor-like weak inducer of apoptosis (TWEAK)-fibroblast growth factor-inducible 14 (Fn14) signaling system regulates glioma cell survival via NFkappaB pathway activation and BCL-XL/BCL-W expression

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

TWEAK promotes ovarian cancer cell metastasis via NF-kappaB pathway activation and VEGF expression

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

An endogenous hybrid mRNA encodes TWE-PRIL, a functional cell surface TWEAK-APRIL fusion protein

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

CD137 stimulation and p38 MAPK inhibition improve reactivity in an in vitro model of glioblastoma immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

Ectopic CD137 expression facilitates the escape of Hodgkin and Reed-Sternberg cells from immunosurveillance

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

Expression of CD137 on Hodgkin and Reed-Sternberg cells inhibits T-cell activation by eliminating CD137 ligand expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

Functional expression of receptor activator of nuclear factor kappaB in Hodgkin disease cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

Expression of receptor activator of nuclear factor kappa-B as a poor prognostic marker in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

Anti-CD40-mediated cancer immunotherapy: an update of recent and ongoing clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

Expression of CD40 ligand (CD154) in B and T lymphocytes of Hodgkin disease: potential therapeutic significance

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

CD40 Ligand--an anti-apoptotic molecule in Hodgkin's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

Phase IA/II, multicentre, open-label study of the CD40 antagonistic monoclonal antibody lucatumumab in adult patients with advanced non-Hodgkin or Hodgkin lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

Circulating levels and clinical significance of soluble CD40 in patients with hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

Isolation of dolastatin 10 from the marine cyanobacterium Symploca species VP642 and total stereochemistry and biological evaluation of its analogue symplostatin 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

Serum levels of soluble CD30 improve International Prognostic Score in predicting the outcome of advanced Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

Soluble CD30 binds to CD153 with high affinity and blocks transmembrane signaling by CD30.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

Inhibition of type 1 cytokine-mediated inflammation by a soluble CD30 homologue encoded by ectromelia (mousepox) virus

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

Histone deacetylase inhibition restores cisplatin sensitivity of Hodgkin's lymphoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

Vorinostat downregulates CD30 and decreases brentuximab vedotin efficacy in human lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

Increased chemosensitivity via targeting testicular nuclear receptor 4 (TR4)-Oct4-interleukin 1 receptor antagonist (IL1Ra) axis in prostate cancer CD133+ stem/progenitor cells to battle prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

Tumour-infiltrating Gr-1+ myeloid cells antagonize senescence in cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

Serum YKL-40 and interleukin 6 levels in Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

Serum CD163 and TARC as disease response biomarkers in classical Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

CD163 and c-Met expression in the lymph node and the correlations between elevated levels of serum free light chain and the different clinicopathological parameters of advanced classical Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

A previously unrecognized protein-protein interaction between TWEAK and CD163: potential biological implications

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

IL-6, but not TNF-α, increases plasma YKL-40 in human subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

Chitinase 3-like 1 regulates cellular and tissue responses via IL-13 receptor α2

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

Interleukin 13 is secreted by and stimulates the growth of Hodgkin and Reed-Sternberg cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

Soluble interleukin-13Ralpha2 decoy receptor inhibits Hodgkin's lymphoma growth in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

Interleukin 13 and interleukin 13 receptor are frequently expressed by Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

EBV Zta protein induces the expression of interleukin-13, promoting the proliferation of EBV-infected B cells and lymphoblastoid cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

Mechanisms of aberrant GATA3 expression in classical Hodgkin lymphoma and its consequences for the cytokine profile of Hodgkin and Reed/Sternberg cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

Targeting the IL-4/IL-13 signaling pathway sensitizes Hodgkin lymphoma cells to chemotherapeutic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

Regulation of JAK2 by miR-135a: prognostic impact in classic Hodgkin lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

The viral load of Epstein-Barr virus (EBV) DNA in peripheral blood predicts for biological and clinical characteristics in Hodgkin lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

Frequent expression of the Epstein-Barr virus (EBV)-induced gene, EBI3, an IL-12 p40-related cytokine, in Hodgkin and Reed-Sternberg cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

Elevated pretreatment serum levels of Il-10 are associated with a poor prognosis in Hodgkin's disease, the milan cancer institute experience

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

Pre-treatment serum levels of interleukin-10, interleukin-12 and their ratio predict response to therapy and probability of event-free and overall survival in childhood soft tissue sarcomas, Hodgkin's lymphomas and acute lymphoblastic leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

Induction of a novel cellular homolog of interleukin-10, AK155, by transformation of T lymphocytes with herpesvirus saimiri

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

Increased serum levels of interleukin-9 correlate to negative prognostic factors in Hodgkin's lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

The T cell-directed CC chemokine TARC is a highly specific biological ligand for CC chemokine receptor 4

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

Macrophage-derived chemokine is a functional ligand for the CC chemokine receptor 4

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

Identification of the CC chemokines TARC and macrophage inflammatory protein-1 beta as novel functional ligands for the CCR8 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

Human chemokines fractalkine (SCYD1), MDC (SCYA22) and TARC (SCYA17) are clustered on chromosome 16q13

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

Hepatitis C virus induces the expression of CCL17 and CCL22 chemokines that attract regulatory T cells to the site of infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

Elevated serum levels of CC thymus and activation-related chemokine (TARC) in primary Hodgkin's disease: potential for a prognostic factor

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

Baseline serum TARC levels predict therapy outcome in patients with Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

Plasma thymus and activation-regulated chemokine as an early response marker in classical Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

Role of fractalkine/CX3CL1 and its receptor in the pathogenesis of inflammatory and malignant diseases with emphasis on B cell malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

Gene expression-based model using formalin-fixed paraffin-embedded biopsies predicts overall survival in advanced-stage classical Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

Human NK cells express CC chemokine receptors 4 and 8 and respond to thymus and activation-regulated chemokine, macrophage-derived chemokine, and I-309.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

Alternative cross-priming through CCL17-CCR4-mediated attraction of CTLs toward NKT cell-licensed DCs.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

Serum VEGF as a significant marker of treatment response in hodgkin lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

Effects of the anti-VEGF monoclonal antibody bevacizumab in a preclinical model and in patients with refractory and multiple relapsed Hodgkin lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

Expression of COX-2 on Reed-Sternberg cells is an independent unfavorable prognostic factor in Hodgkin lymphoma treated with ABVD.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

Prognostic significance of COX-2 expression and correlation with Bcl-2 and VEGF expression, microvessel density, and clinical variables in classical Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

Expression of cyclooxygenase-2 in Hodgkin's lymphoma: its role in cell proliferation and angiogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

CSF-1R expression in tumor-associated macrophages is associated with worse prognosis in classical Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

Derepression of an endogenous long terminal repeat activates the CSF1R proto-oncogene in human lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

Expression and Regulation of the Endogenous Retrovirus 3 in Hodgkin's Lymphoma Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

Expression of dual-specificity phosphatase 5 pseudogene 1 (DUSP5P1) in tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

Soluble interleukin-2 receptors (sIL-2R) in Hodgkin's disease: outcome and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

Insights into heparin-induced thrombocytopenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

Expression of cancer testis antigen CT45 in classical Hodgkin lymphoma and other B-cell lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

Characterization and expression of CT45 in Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

Knock-down of PRAME increases retinoic acid signaling and cytotoxic drug sensitivity of Hodgkin lymphoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

Limited usefulness of CA125 measurement in the management of Hodgkin's and non-Hodgkin's lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

The histone variant H2A.Bbd is enriched at sites of DNA synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

Microsatellite instability and Beta2-Microglobulin mutations as prognostic markers in colon cancer: results of the FOGT-4 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

Increased PRAME antigen-specific killing of malignant cell lines by low avidity CTL clones, following treatment with 5-Aza-2'-Deoxycytidine

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

A causal role for the human tumor antigen preferentially expressed antigen of melanoma in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

Gene expression profiling predicts clinical outcome of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

Hodgkin's lymphoma RNA-transfected dendritic cells induce cancer/testis antigen-specific immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

Gene expression profiling of microdissected Hodgkin Reed-Sternberg cells correlates with treatment outcome in classical Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

Galectin-1 serum levels reflect tumor burden and adverse clinical features in classical Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

Current status of prognostication in classical Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

The AP1-dependent secretion of galectin-1 by Reed Sternberg cells fosters immune privilege in classical Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

Galectin-1-mediated cell death is increased by CD30-induced signaling in anaplastic large cell lymphoma cells but not in Hodgkin lymphoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

Galectin-1 mediated suppression of Epstein-Barr virus specific T-cell immunity in classic Hodgkin lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

Expression of the human germinal center-associated lymphoma (HGAL) protein identifies a subset of classic Hodgkin lymphoma of germinal center derivation and improved survival

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

Germinal centre protein HGAL promotes lymphoid hyperplasia and amyloidosis via BCR-mediated Syk activation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

The transcription factors Blimp-1 and IRF4 jointly control the differentiation and function of effector regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

MicroRNA-mediated down-regulation of PRDM1/Blimp-1 in Hodgkin/Reed-Sternberg cells: a potential pathogenetic lesion in Hodgkin lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

Evidence of abortive plasma cell differentiation in Hodgkin and Reed-Sternberg cells of classical Hodgkin lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

CD99 triggers upregulation of miR-9-modulated PRDM1/BLIMP1 in Hodgkin/Reed-Sternberg cells and induces redifferentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

FOXO1 repression contributes to block of plasma cell differentiation in classical Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

Variants at 6q21 implicate PRDM1 in the etiology of therapy-induced second malignancies after Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

Plasma microRNA are disease response biomarkers in classical Hodgkin lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

Impact of O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation and MGMT expression on dacarbazine resistance of Hodgkin's lymphoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

DNA-microarrays as tools for the identification of tumor specific gene expression profiles: applications in tumor biology, diagnosis and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

Tumor-associated macrophages and survival in classic Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

Gene Expression Profiling forIn SilicoMicrodissection of Hodgkin's Lymphoma Microenvironment and Identification of Prognostic Features

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

Tumor-infiltrating macrophages correlate with adverse prognosis and Epstein-Barr virus status in classical Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

CD163 expression was associated with angiogenesis and shortened survival in patients with uniformly treated classical Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 Intergroup trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

The prognostic relevance of tumor associated macrophages in advanced stage classical Hodgkin lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

Immunohistochemical markers for tumor associated macrophages and survival in advanced classical Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

CD68 tumor-associated macrophage marker is not prognostic of clinical outcome in classical Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

The prognostic impact of tumour-associated macrophages and Reed-Sternberg cells in paediatric Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

The EuroNet paediatric hodgkin network - modern imaging data management for real time central review in multicentre trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

Membrane-anchored CD40 Is Processed by the Tumor Necrosis Factor-α-converting Enzyme

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

Serum chemokine levels in Hodgkin lymphoma patients: highly increased levels of CCL17 and CCL22

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

Plasma Cytokine and Soluble Receptor Signature Predicts Outcome of Patients With Classical Hodgkin's Lymphoma: A Study From the Groupe d'Etude des Lymphomes de l'Adulte

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

Proteomic analysis identifies galectin-1 as a predictive biomarker for relapsed/refractory disease in classical Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

Tumor microenvironment and mitotic checkpoint are key factors in the outcome of classic Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

High serum levels of B-lymphocyte stimulator are associated with clinical?pathological features and outcome in classical Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

Very high levels of soluble CD30 recognize the patients with classical Hodgkin's lymphoma retaining a very poor prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08880018.2015.1071903

10.3109/08880018.2015.1071903

21 January 2018

Identifiers

DOI

1 reference

4 September 2017

1 reference